The multifaceted role of MUC1 in tumor therapy resistance
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG..
Tumor therapeutic resistances are frequently linked to the recurrence and poor prognosis of cancers and have been a key bottleneck in clinical tumor treatment. Mucin1 (MUC1), a heterodimeric transmembrane glycoprotein, exhibits abnormally overexpression in a variety of human tumors and has been confirmed to be related to the formation of therapeutic resistance. In this review, the multifaceted roles of MUC1 in tumor therapy resistance are summarized from aspects of pan-cancer principles shared among therapies and individual mechanisms dependent on different therapies. Concretely, the common mechanisms of therapy resistance across cancers include interfering with gene expression, promoting genome instability, modifying tumor microenvironment, enhancing cancer heterogeneity and stemness, and activating evasion and metastasis. Moreover, the individual mechanisms of therapy resistance in chemotherapy, radiotherapy, and biotherapy are introduced. Last but not least, MUC1-involved therapy resistance in different types of cancers and MUC1-related clinical trials are summarized.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Clinical and experimental medicine - 23(2023), 5 vom: 23. Sept., Seite 1441-1474 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jin, Weiqiu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biotherapy |
|---|
| Anmerkungen: |
Date Completed 29.08.2023 Date Revised 29.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10238-022-00978-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350761922 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350761922 | ||
| 003 | DE-627 | ||
| 005 | 20231226045728.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10238-022-00978-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1169.xml |
| 035 | |a (DE-627)NLM350761922 | ||
| 035 | |a (NLM)36564679 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jin, Weiqiu |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The multifaceted role of MUC1 in tumor therapy resistance |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.08.2023 | ||
| 500 | |a Date Revised 29.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG. | ||
| 520 | |a Tumor therapeutic resistances are frequently linked to the recurrence and poor prognosis of cancers and have been a key bottleneck in clinical tumor treatment. Mucin1 (MUC1), a heterodimeric transmembrane glycoprotein, exhibits abnormally overexpression in a variety of human tumors and has been confirmed to be related to the formation of therapeutic resistance. In this review, the multifaceted roles of MUC1 in tumor therapy resistance are summarized from aspects of pan-cancer principles shared among therapies and individual mechanisms dependent on different therapies. Concretely, the common mechanisms of therapy resistance across cancers include interfering with gene expression, promoting genome instability, modifying tumor microenvironment, enhancing cancer heterogeneity and stemness, and activating evasion and metastasis. Moreover, the individual mechanisms of therapy resistance in chemotherapy, radiotherapy, and biotherapy are introduced. Last but not least, MUC1-involved therapy resistance in different types of cancers and MUC1-related clinical trials are summarized | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Biotherapy | |
| 650 | 4 | |a Cancer therapy resistance | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a MUC1 | |
| 650 | 4 | |a Radiation therapy | |
| 650 | 7 | |a Mucin-1 |2 NLM | |
| 650 | 7 | |a MUC1 protein, human |2 NLM | |
| 700 | 1 | |a Zhang, Mengwei |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Changzi |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Qingquan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental medicine |d 2001 |g 23(2023), 5 vom: 23. Sept., Seite 1441-1474 |w (DE-627)NLM113691408 |x 1591-9528 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:5 |g day:23 |g month:09 |g pages:1441-1474 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10238-022-00978-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 5 |b 23 |c 09 |h 1441-1474 | ||